Dr Reddy's Laboratories, an integrated global pharmaceutical company, on Monday announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) tablets approved by the U.S. Food and Drug Administration (USFDA).

According to IQVIA Health, the Uloric brand and generic had U.S. sales of approximately USD 108 million MAT for the most recent twelve months ending in October 2020.

The company's Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.

Shares of the company gained Rs 79.30, or 1.49%, to settle  at  Rs 5,416.60.  The total volume of shares traded  was  27,806 at  the BSE (Monday).